Bristol’s New Products Meet Early Launch Expectations

Even So, Currency Changes Lead To Lowered Revenue Guidance

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.

SECOND QUARTER text on a sticker on notebook, wooden background
Bristol's Q2 revenue of $11.89bn exceeded analyst consensus • Source: Shutterstock

Even with second quarter sales of its former top-seller Revlimid (lenalidomide) down 22% from Q2 of last year due to generic competition in the US and EU, Bristol Myers Squibb Company reported total revenue of $11.89bn on 27 July, beating analyst consensus of $11.42bn for the quarter. Blockbusters, including Eliquis (apixaban) and Opdivo (nivolumab) accounted for most of the dollar growth, but newer products saw big percentage gains and had encouraging initial launches.

But while Bristol still expects growth for its in-line and new product portfolio, with no change in its guidance of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.